“morphosys” Archives

in
Entry Author Date Location
Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More 08/07/20 National
MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T 08/03/20 Europe
Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More 01/17/20 National
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug 01/13/20 National
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight 08/28/19 New York
Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More 06/28/19 National
15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) 12/17/18 National
Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More 07/20/18 National
Surface Oncology’s Upsized IPO Reels In $108M for Lead Cancer Drug 04/18/18 Boston
East Coast Biotech Roundup: Hemophilia, Levin, Vertex, Semma & More 03/27/15 Boston
West Coast Biotech Roundup: Ebola, Mapp, Tekmira, ViaCyte & More 08/21/14 San Diego
Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker 08/05/13 National
East Coast Life Sciences Roundup: J&J, Celgene, Zafgen, & More 06/28/13 Boston
Ablexis Maps Out New Antibody Drug Strategy with $12M From Third Rock, Pfizer 06/23/10 San Francisco
Adimab Proves Fast Antibody Discovery Tool to Merck, Roche; Snags New Deal With Pfizer 12/17/09 Boston
Page 1 of 1